API
< Back to all clusters
[HEALTH] · United States · 2 sources

started · updated

Galinpepimut-S vaccine reduces leukemia death risk by 41%

Sellas Life Sciences and Memorial Sloan Kettering Cancer Center have announced positive results from a Phase 3 clinical trial for galinpepimut-S (GPS), a vaccine designed to treat acute myeloid leukemia (AML). The trial, which included 126 patients, demonstrated that the vaccine reduced the risk of death by 41% compared to other leukemia treatments.

The study focused on patients who had achieved a second or subsequent complete remission. While AML is typically treated with chemotherapy, residual cancer cells often lead to frequent relapses. Unlike personalized mRNA vaccines such as intismeran, which require individual tumor samples for production, GPS is designed as an off-the-shelf formulation that can be administered to all patients using the same preparation.

David Sanguinetti, president of the Experimental Therapeutics Center at Memorial Sloan Kettering and the creator of GPS, noted that the vaccine is potentially ready-to-use without the need for individual redesign for every patient.

Entities

David Sanguinetti · Memorial Sloan Kettering Cancer Center · Sellas Life Sciences · galinpepimut-S